10/18/2012 9:47:32 AM
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces the termination of its proposed convertible preferred stock offering because of current market conditions. Provectus filed a preliminary prospectus supplement with the Securities and Exchange Commission on September 4, 2012, with respect to the proposed offering. As disclosed in the Company's filings with the Securities and Exchange Commission, the Company expects to seek additional financing to fund its operations.
comments powered by